Want to learn more about VOXZOGO? Get email updates or get in touch with a local BioMarin representative
Most bones start to grow before birth and continue for as long as the bones’ growth plates stay open. While the growth plates are open, there is an opportunity for growth.
Achondroplasia affects endochondral bone growth—this is bone growth that replaces cartilage with bone tissue as your child grows. Endochondral bone growth occurs in over 90% of bones in the body and takes place at the growth plate.
A balance between fibroblast growth factor receptor 3 (FGFR3) and C-type natriuretic peptide (CNP) signaling pathways occurs within the cells in the growth plate.
FGFR3 slows bone growth while CNP promotes bone growth
In achondroplasia, FGFR3 sends more signals to slow bone growth than it should. The body’s CNP is not enough to balance overactive FGFR3 signaling.
Achondroplasia tilts the balance and slows down bone growth
VOXZOGO works alongside the body’s natural CNP to stimulate the CNP signaling pathway to promote bone growth.
Want to learn more about VOXZOGO? Get email updates or get in touch with a local BioMarin representative
What is the most important safety information about VOXZOGO?
What are the most common side effects of VOXZOGO?
How is VOXZOGO taken?
What should you tell the doctor before or during taking VOXZOGO?
You may report side effects to BioMarin at 1-866-906-6100. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see additional safety information in the full Prescribing Information and Patient Information.
What is VOXZOGO used for?